Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

E-resources

PDF

Peer reviewed Open access

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

Andrews, Nick; Tessier, Elise; Stowe, Julia; Gower, Charlotte; Kirsebom, Freja; Simmons, Ruth; Gallagher, Eileen; Thelwall, Simon; Groves, Natalie; Dabrera, Gavin; Myers, Richard; Campbell, Colin N.J; Amirthalingam, Gayatri; Edmunds, Matt; Zambon, Maria; Brown, Kevin; Hopkins, Susan; Chand, Meera; Ladhani, Shamez N; Ramsay, Mary; Lopez Bernal, Jamie

New England journal of medicine/The New England journal of medicine, 01/2022, Volume: 386, Issue: 4

Journal Article

A test-negative case–control study involving more than 6 million persons in England who received two doses of the ChAdOx1-S or BNT162b2 vaccine (interval, 3 to 12 weeks) showed high vaccine effectiveness against hospitalization and death from Covid-19 at 20 weeks or more after vaccination. Protection against infection waned. Waning was greater in older persons and those with underlying risk factors.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme